Hepatitis: Pathophysiology and Treatment

Hepatitis is the inflammation of the liver caused by viral infections, toxins, autoimmune diseases, or other factors. Viral hepatitis is the most common cause, categorized by types A, B, C, D, E, and a less-known F (though F remains debated as a separate entity). Each type differs in mode of transmission, clinical course, and long-term consequences.

Symptoms of Hepatitis

• Fatigue, weakness
• Fever, nausea, vomiting
• Abdominal pain (right upper quadrant)
• Dark urine, pale stools
• Jaundice (yellowing of skin & eyes)
• In chronic hepatitis: cirrhosis, ascites, easy bruising, liver cancer

Hepatitis A (HAV)

Hepatitis A (HAV) is caused by the Hepatitis A virus, a non-enveloped RNA virus from the Picornaviridae family. The virus is primarily transmitted through the fecal-oral route, often via contaminated food and water, or through close personal contact with an infected person. The incubation period for HAV ranges from 15 to 50 days, with an average of approximately 28 days. Symptoms of the infection include fever, fatigue, nausea, and vomiting. In severe cases, jaundice may develop, along with dark urine and pale stools. Diagnosis is typically made through the detection of Anti-HAV IgM, which indicates an acute infection, and Anti-HAV IgG, which shows immunity or vaccination status.

Treatment: Treatment for Hepatitis A is mainly supportive, as the infection usually resolves spontaneously with hydration and rest. Prevention of HAV infection is achieved through vaccination and improvements in sanitation and hygiene. The prognosis is generally favorable as the disease is self-limiting and does not progress to a chronic stage. Acute liver failure is a rare complication of the infection.

Hepatitis B (HBV)

Hepatitis B (HBV) is caused by the Hepatitis B virus, an enveloped DNA virus from the Hepadnaviridae family. The virus is transmitted through blood, sexual contact, and from mother to child during childbirth. It can also spread through sharing needles or exposure to infected blood. The incubation period for HBV ranges from 4 to 24 weeks, with an average of approximately 10 weeks. Many individuals with HBV remain asymptomatic, especially during the acute phase, which may present with fever, joint pain, jaundice, and abdominal pain. In the chronic phase, the infection can lead to severe complications such as cirrhosis and liver cancer. Diagnosis is based on serological markers, including HBsAg, which indicates current infection, Anti-HBc IgM for recent or acute infection, and Anti-HBs for immunity from recovery or vaccination.

Treatment: Treatment for acute HBV involves supportive care, while chronic HBV is managed with antiviral medications like entecavir or tenofovir, along with interferon therapy. The most effective prevention method is the HBV vaccine, along with practicing safe sex and ensuring blood safety. The prognosis is generally favorable for acute HBV, with around 90% of patients recovering, but 5–10% of cases progress to chronic infection, which can lead to cirrhosis or hepatocellular carcinoma.

Hepatitis C (HCV)

Hepatitis C (HCV) is caused by the Hepatitis C virus, an enveloped RNA virus belonging to the Flaviviridae family. The primary mode of transmission is blood-to-blood contact, often through sharing needles or unsterilized medical equipment. Although it is rarely transmitted through sexual contact, it can still occur. The incubation period for HCV ranges from 2 to 26 weeks, with an average of approximately 6 to 7 weeks. Many individuals with HCV remain asymptomatic, but in the chronic phase, symptoms may include fatigue, joint pain, jaundice, and liver damage. Diagnosis typically involves screening for Anti-HCV antibodies, followed by confirmation with HCV RNA testing.

Treatment: Treatment for HCV has been revolutionized by direct-acting antivirals (DAAs), which offer cure rates exceeding 95%. Notable DAAs include Sofosbuvir and Ledipasvir. While no vaccine is currently available for HCV, prevention strategies focus on blood safety and needle exchange programs. In terms of prognosis, approximately 15–25% of individuals clear the infection spontaneously, while 75–85% develop chronic HCV, which increases the risk of cirrhosis and liver cancer.

Hepatitis D (HDV)

Hepatitis D (HDV) is caused by the Hepatitis D virus, a defective RNA virus that requires co-infection with Hepatitis B virus (HBV) for replication. The transmission of HDV is similar to that of HBV, including blood, sexual contact, and mother-to-child transmission. The incubation period for HDV ranges from 3 to 13 weeks. Infected individuals often experience more severe symptoms compared to HBV alone, and HDV accelerates liver damage in those with co-infection. Diagnosis is made through the detection of Anti-HDV antibodies and HDV RNA.

Treatment: There is no specific antiviral therapy for HDV, although interferon-alpha may provide some benefit in certain cases. Prevention of HDV infection is effectively achieved by receiving the HBV vaccine, as this prevents HDV co-infection. Additionally, avoiding high-risk behaviors such as sharing needles or engaging in unprotected sex is essential. The prognosis of HDV infection is poor in cases of co-infection or superinfection with HBV, as it can lead to rapid progression to cirrhosis.

Hepatitis E (HEV)

Hepatitis E (HEV) is caused by the Hepatitis E virus, a non-enveloped RNA virus from the Hepeviridae family. The virus is primarily transmitted through the fecal-oral route, with contaminated water being a major source of infection, especially in developing countries. Zoonotic transmission can occur in some regions through undercooked meat. The incubation period for HEV ranges from 2 to 10 weeks, with an average of approximately 6 weeks. The symptoms of HEV are similar to Hepatitis A, including fever, jaundice, and nausea. However, HEV infection is particularly severe in pregnant women, who face a high mortality risk. Diagnosis of HEV is made through the detection of Anti-HEV IgM and IgG antibodies, as well as HEV RNA in blood or stool.

Treatment: Most cases of HEV resolve with supportive care, but ribavirin may be used in severe or chronic cases, particularly in immunocompromised individuals. Preventive measures include improved sanitation, access to safe drinking water, and, in some regions, the availability of an HEV vaccine. The prognosis for most individuals is favorable, as the infection is self-limiting. However, in immunocompromised patients, HEV can cause chronic infection.

Hepatitis F

Hepatitis F is a hypothetical hepatitis virus that has not been universally recognized or confirmed. Its existence remains debated, and it is unclear whether it represents a new virus or a variant of known hepatitis viruses. Due to the lack of scientific validation, Hepatitis F is not considered an established entity. The symptoms and diagnosis of Hepatitis F are indistinct, often overlapping with those of other hepatitis types. As of now, Hepatitis F does not have scientific recognition as a separate form of hepatitis, and its transmission remains unclear.

Pathophysiology of Hepatitis

Step 1: Entry of the Virus

Hepatitis viruses (A, B, C, D, E, F) enter the body in different ways:

• Hepatitis A & E → spread mainly through the fecal-oral route (contaminated food/water).
• Hepatitis B, C & D → spread through blood, sexual contact, or mother-to-child.
• Hepatitis F (rare/uncertain) → proposed as a new type, not fully established.

Step 2: Reaching the Liver

After entry, the virus travels through the bloodstream and reaches the liver. The viruses specifically target hepatocytes (liver cells), which are their main site of infection.

Step 3: Viral Multiplication

Inside hepatocytes, the viruses use the host’s machinery to multiply. Different viruses have slightly different replication mechanisms (for example, Hepatitis B is a DNA virus with reverse transcription, while others are RNA viruses), but the result is the same → production of many new viral particles.

Step 4: Immune Response and Inflammation

The body’s immune system recognizes infected liver cells.

• Cytotoxic T lymphocytes attack and destroy infected hepatocytes to stop viral spread.
• This immune attack, rather than the virus itself, causes inflammation and liver cell injury.

Step 5: Liver Damage and Dysfunction

When hepatocytes are damaged:

• The liver cannot process bilirubin effectively → leading to jaundice.
• Inflammation causes the liver to enlarge (hepatomegaly) and become tender.
• In chronic cases (especially Hepatitis B, C, D), continuous damage leads to fibrosis, cirrhosis, and increased risk of liver cancer (hepatocellular carcinoma).

Step 6: Differences Between Types

• Hepatitis A & E → Acute, self-limiting infections; usually no chronic disease.
• Hepatitis B & C → Can become chronic; high risk of cirrhosis and liver cancer.
• Hepatitis D → Needs Hepatitis B to survive (co-infection or superinfection); makes B infection more severe.
• Hepatitis F → Still under research; not widely recognized as a separate virus.

Step 7: Clinical Effects

Patients may develop fatigue, loss of appetite, nausea, abdominal pain, dark urine, pale stools, and jaundice. Severe cases may progress to liver failure, while chronic hepatitis can silently damage the liver for years.

Comparison of Hepatitis Types

Hepatitis presents a spectrum of challenges ranging from self-limiting acute infections to life-threatening chronic conditions. Early diagnosis, public health measures, vaccination, and advancements in antiviral therapies have significantly improved outcomes, but challenges like vaccine availability and global healthcare inequities remain.

Visit to: Pharmacareerinsider.com